{"id":4605,"date":"2026-03-04T15:25:27","date_gmt":"2026-03-04T12:25:27","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4605"},"modified":"2026-03-05T16:42:10","modified_gmt":"2026-03-05T13:42:10","slug":"obezite-kisisel-bir-tercih-degil-tibbi-tedaviyle-yonetilmesi-gereken-bir-hastaliktir","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4605","title":{"rendered":"Obezite Ki\u015fisel Bir Tercih De\u011fil, T\u0131bbi Tedaviyle Y\u00f6netilmesi Gereken Bir Hastal\u0131kt\u0131r"},"content":{"rendered":"\n<p><strong>Obezite; v\u00fccutta ya\u011f dokusunun art\u0131\u015f\u0131yla ili\u015fkili, kronik, tekrarlay\u0131c\u0131 ve tedavi edilebilir bir hastal\u0131k olarak tan\u0131mlan\u0131yor ve bug\u00fcn d\u00fcnya genelinde yakla\u015f\u0131k 1 milyar insan\u0131 etkiliyen bir salg\u0131n boyutuna ula\u015fm\u0131\u015f durumda.<sup>1 &nbsp;<\/sup>4 Mart D\u00fcnya Obezite G\u00fcn\u00fc kapsam\u0131nda Lilly, obezite ile ilgili yanl\u0131\u015f alg\u0131lar\u0131n bireylerin ya\u015fam\u0131n\u0131 zorla\u015ft\u0131rd\u0131\u011f\u0131na dikkat \u00e7ekiyor ve damgalamadan uzak, bilim temelli bir bak\u0131\u015f a\u00e7\u0131s\u0131n\u0131n \u00f6nemine i\u015faret ediyor.<\/strong><\/p>\n\n\n\n<p>Obezite hastal\u0131\u011f\u0131; tip 2 diyabet, kalp hastal\u0131\u011f\u0131, inme ve baz\u0131 kanser t\u00fcrleri dahil olmak \u00fczere bir\u00e7ok ciddi hastal\u0131\u011fa yol a\u00e7abiliyor. Bu hastal\u0131klar ya\u015fam kalitesini d\u00fc\u015f\u00fcr\u00fcyor ve erken \u00f6l\u00fcm riskini art\u0131r\u0131yor.<sup>2,3<\/sup> Obeziteli ki\u015filer bir tercihle de\u011fil, bir hastal\u0131kla ya\u015f\u0131yor. Bu durum fiziksel, zihinsel, duygusal ve sosyal engelleri de beraberinde getiriyor.<\/p>\n\n\n\n<p>Son derece ciddi bir hastal\u0131\u011fa sahip olan bu ki\u015filerin maruz kald\u0131\u011f\u0131 baz\u0131 engeller, sa\u011fl\u0131k hizmetlerine eri\u015fimlerini de olumsuz etkiliyor. Bunun temel nedeni, obezitenin kronik, tekrarlay\u0131c\u0131 ve ilerleyici bir hastal\u0131k olarak alg\u0131lanmamas\u0131.<\/p>\n\n\n\n<p><strong>Obezite hastal\u0131\u011f\u0131 ile ilgili yanl\u0131\u015f alg\u0131lar\u0131n sorgulanmas\u0131 gerekiyor<\/strong><\/p>\n\n\n\n<p>IPSOS&#8217;un, D\u00fcnya Obezite G\u00fcn\u00fc&#8217;nde yay\u0131nlanan &#8220;Obezite Alg\u0131s\u0131 Ara\u015ft\u0131rmas\u0131&#8221;, obezitenin t\u0131bbi ger\u00e7ekli\u011fi ile bu hastal\u0131kla ya\u015fayan ki\u015filerin deneyimleri aras\u0131nda derin bir fark oldu\u011funu ortaya koyuyor.<sup>4<\/sup><\/p>\n\n\n\n<p>IPSOS&#8217;un 14 \u00fclkede ger\u00e7ekle\u015fen son ara\u015ft\u0131rmas\u0131n\u0131n sonu\u00e7lar\u0131na g\u00f6re:<\/p>\n\n\n\n<ul>\n<li>Obeziteli ki\u015filerin y\u00fczde 71&#8217;i, obezitenin s\u00fcrekli tedavi gerektiren bir sa\u011fl\u0131k sorunu oldu\u011fu g\u00f6r\u00fc\u015f\u00fcne kat\u0131l\u0131yor.<\/li>\n\n\n\n<li>Y\u00fczde 66&#8217;s\u0131 obeziteyi ki\u015fisel tercihlerle \u00f6nlenebilir olarak g\u00f6r\u00fcyor y\u00fczde 63&#8217;\u00fc &#8220;diyet ve egzersizle \u00e7o\u011fu insan\u0131n obezite sorununu \u00e7\u00f6zebilece\u011fi&#8221; fikrine sahip.<\/li>\n\n\n\n<li>Obeziteli ki\u015filerin yar\u0131s\u0131, genetik ve biyolojik fakt\u00f6rlerin obezitenin temel nedenleri aras\u0131nda yer ald\u0131\u011f\u0131n\u0131 kabul ediyor.<\/li>\n<\/ul>\n\n\n\n<p>Ara\u015ft\u0131rma sonu\u00e7lar\u0131, kat\u0131l\u0131mc\u0131lar\u0131n i\u00e7sel bir \u00e7at\u0131\u015fma ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Obezitenin t\u0131bbi bir hastal\u0131k oldu\u011funun fark\u0131ndalar ancak bu durumu kendi davran\u0131\u015flar\u0131n\u0131n sonucu olarak g\u00f6r\u00fcyorlar.<\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><a href=\"https:\/\/go.lilly.com\/q\/pharmaworld-obh\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"487\" src=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/03\/Pharmaworld-2648x1260-5-1024x487.jpg\" alt=\"\" class=\"wp-image-4625\" style=\"width:544px;height:auto\" srcset=\"https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/03\/Pharmaworld-2648x1260-5-1024x487.jpg 1024w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/03\/Pharmaworld-2648x1260-5-300x143.jpg 300w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/03\/Pharmaworld-2648x1260-5-768x365.jpg 768w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/03\/Pharmaworld-2648x1260-5-1536x731.jpg 1536w, https:\/\/pharmaworlddergi.com\/wp-content\/uploads\/2026\/03\/Pharmaworld-2648x1260-5-2048x975.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure><\/div>\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><strong>T\u00fcrkiye\u2019de alg\u0131, tedavinin \u00f6n\u00fcne ge\u00e7iyor<\/strong><\/p>\n\n\n\n<p>Ara\u015ft\u0131rman\u0131n T\u00fcrkiye verileri, fark\u0131ndal\u0131k ve eylem aras\u0131nda fark oldu\u011funu g\u00f6steriyor.<sup>4 <\/sup>Obeziteli ki\u015filerin \u00e7ok b\u00fcy\u00fck bir k\u0131sm\u0131 (y\u00fczde 80) kilolar\u0131n\u0131 kontrol etmeyi d\u00fc\u015f\u00fcnd\u00fcklerini veya bu konuda tavsiye ald\u0131klar\u0131n\u0131 belirtirken, sadece y\u00fczde 35&#8217;i son bir y\u0131l i\u00e7inde bir doktora dan\u0131\u015fm\u0131\u015f. Buradaki temel engel bilgi eksikli\u011fi de\u011fil, alg\u0131. T\u00fcrkiye&#8217;de obeziteli ki\u015filerin y\u00fczde 45&#8217;i &#8220;Kilomu kendi ba\u015f\u0131ma kontrol etmeyi tercih ederim&#8221; diyor. Bu oran bir\u00e7ok \u00fclkeye k\u0131yasla \u00f6nemli \u00f6l\u00e7\u00fcde y\u00fcksek. Bulgular, ki\u015fisel sorumluluk inanc\u0131n\u0131n ne kadar derin k\u00f6kleri oldu\u011funu ortaya koyuyor. Bu da s\u0131kl\u0131kla obezitenin kronik bir hastal\u0131k olarak ele al\u0131nmas\u0131n\u0131 zorla\u015ft\u0131r\u0131rken mevcut t\u0131bbi deste\u011fe eri\u015fimi de geciktiriyor.<\/p>\n\n\n\n<p>2025 y\u0131l\u0131 i\u00e7in Ar-Ge yat\u0131r\u0131m\u0131 13,3 milyar ABD dolar\u0131olan Lilly, hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftiren ve sa\u011fl\u0131k sistemleri \u00fczerindeki uzun vadeli y\u00fck\u00fc azaltan s\u00fcrd\u00fcr\u00fclebilir \u00e7\u00f6z\u00fcmleri geli\u015ftirmeye kararl\u0131 bir \u015fekilde faaliyet g\u00f6steriyor. Lilly, obezite hastal\u0131\u011f\u0131 ile m\u00fccadelede ba\u015far\u0131n\u0131n kamu, d\u00fczenleyiciler, akademi ve \u00f6zel sekt\u00f6r aras\u0131ndaki g\u00fc\u00e7l\u00fc i\u015fbirli\u011fine ba\u011fl\u0131 oldu\u011funu da vurguluyor. Bu ba\u011flamda Lilly, T\u00fcrkiye&#8217;nin Ulusal Obezite Stratejik Plan\u0131 \u00e7er\u00e7evesinde i\u015fbirli\u011fini derinle\u015ftirmeyi hedefliyor.<\/p>\n\n\n\n<p>Referanslar:<\/p>\n\n\n\n<p>1 TEMD obezite k\u0131lavuzu 2024<\/p>\n\n\n\n<p>2 World Obesity Atlas 2025. March 2025.<\/p>\n\n\n\n<p>3 NCDs. Accessed February 25,2025. https:\/\/ncdalliance.org\/why-ncds\/NCDs<\/p>\n\n\n\n<p>4 Gloval Perceptions of Obesity Study- Under embargo until 4 March 2026<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Obezite; v\u00fccutta ya\u011f dokusunun art\u0131\u015f\u0131yla ili\u015fkili, kronik, tekrarlay\u0131c\u0131 ve tedavi edilebilir bir hastal\u0131k olarak tan\u0131mlan\u0131yor ve bug\u00fcn d\u00fcnya genelinde yakla\u015f\u0131k 1 milyar insan\u0131 etkiliyen bir salg\u0131n boyutuna ula\u015fm\u0131\u015f durumda.1 \u00a04 Mart D\u00fcnya Obezite G\u00fcn\u00fc kapsam\u0131nda Lilly, obezite ile ilgili yanl\u0131\u015f alg\u0131lar\u0131n bireylerin ya\u015fam\u0131n\u0131 zorla\u015ft\u0131rd\u0131\u011f\u0131na dikkat \u00e7ekiyor ve damgalamadan uzak, bilim temelli bir bak\u0131\u015f a\u00e7\u0131s\u0131n\u0131n \u00f6nemine i\u015faret ediyor.<\/p>\n","protected":false},"author":1,"featured_media":4630,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,42],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4605"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4605"}],"version-history":[{"count":14,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4605\/revisions"}],"predecessor-version":[{"id":4635,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4605\/revisions\/4635"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4630"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}